StemRIM AAQS

Que fait StemRIM ? StemRIM Inc is a biotechnology company based in Ibaraki-shi, Japan, operating within the Health Care sector. The company focuses on the research and development of regeneration-inducing medicines, specifically developing pharmaceuticals that promote functional regeneration and healing of damaged biological tissues without the use of living cells or tissues. StemRIM Inc went public via an IPO on August 9, 2019, and currently employs 44 full-time staff members. The company's primary product is a stem cell regeneration-inducing medicine, which aims to deliver therapeutic effects similar to regenerative medicine through oral administration alone, eliminating the need for live cell or tissue transplantation. StemRIM Inc maintains a website at stemrim.com, though specific details about its product development stage, clinical trials, or commercialization status are not provided in the available information. The company's headquarters are located in Ibaraki-shi, and it is listed on the Tokyo Stock Exchange under the ticker 4599.T with ISIN JP3399690001. No additional details about its founding year, key personnel, acquisitions, or financial figures are included in the provided data. StemRIM est l'une des entreprises les plus populaires sur Eulerpool.